Human cytomegalovirus in uterotransmission: Follow-up of 524 maternal seroconversions
Bodéus M, Zech F, Hubinont C, et al. Human cytomegalovirus in uterotransmission: follow-up of 524 maternal seroconversions. J Clin Virol 2010;47:201-2.
Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy: A case-control study of the outcome in children
Nigro G, Adler SP, Parruti G, et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy: a case-control study of the outcome in children. J Infect Dis 2012;205:215-22.
The Food and Drug Administration(FDA) Center for Biologics Evaluation and Research (CBER) the National Institutes of Health the National Institute of Allergy and Infectious Diseases (NIAID) the Centers for Disease Control and Prevention and the National Vaccine Program Office [last accessed 10 Jan 2012]
Revello MG. Role of antibodies and CMI in preventing congenital CMV. The Development and Evaluation of Human Cytomegalovirus Vaccines, Public Workshop, 10 January 2012. The Food and Drug Administration(FDA) Center for Biologics Evaluation and Research (CBER), the National Institutes of Health, the National Institute of Allergy and Infectious Diseases (NIAID), the Centers for Disease Control and Prevention and the National Vaccine Program Office. Available from: http://videocast.nih.gov/pastevents.asp?c=1 [last accessed 10 Jan 2012].
Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: A retrospective analysis
Buxmann H, Stackelberg OM, Schlöber L, et al. Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis. J Perinat Med 2012;40:439-46.
Placental enlargement in women with a primary maternal cytomegalovirus infection is associated with fetal and neonatal disease
La Torre R, Nigro G, Mazzocco M, et al. Placental enlargement in women with a primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. Clin Infect Dis 2006;43: 994-1000.
Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection
Maidji E, Nigro G, Tabata T, et al. Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection. Am J Pathol 2010;177:1298-310.